Amphastar Pharmaceuticals, Inc. (AMPH) AI Stock Analysis

Amphastar Pharmaceuticals, Inc. develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal pharmaceutical products. It operates through two primary segments: Finished Pharmaceutical Products and API, serving markets across the United States, China, and France. Its portfolio includes medications such as Primatene Mist for mild asthma symptoms, Enoxaparin for deep vein thrombosis, Naloxone for opioid overdose reversal, and Glucagon emergency kits for severe hypoglycemia. It also supplies Cortrosyn for adrenal insufficiency screening, Epinephrine injections, Amphadase, and lidocaine products. Amphastar distributes products to hospitals, clinics, doctors' offices, and alternate care sites.

Between FY2021 and FY2025, Amphastar achieved a 5-year revenue compound annual growth rate of 15.5%. Annual revenue increased from $437.8M in FY2021 to a peak of $732.0M in FY2024 before revenue fell 1.7% to $719.9M in FY2025. Over the same period, net income moved from $62.1M in FY2021 to $159.5M in FY2024, followed by a decline to $98.1M in FY2025 as operating margin contracted to 19.5%. In the latest quarter ended June 30, 2026, quarterly revenue grew 5.4% year-over-year, while quarterly earnings grew 4.7%. For the trailing twelve months, revenue was $730.0M and diluted earnings per share stood at $1.69.

As of June 30, 2026, Amphastar held $290.1M in cash and short-term investments alongside total debt of $688.3M, resulting in net debt of $398.2M. Total assets stood at $1.74B against shareholders' equity of $768.2M, with a current ratio of 2.40 and a debt-to-equity ratio of 0.90. In FY2025, operating cash flow was $156.1M and free cash flow was $121.2M. Capital expenditures totaled $34.9M and share buybacks absorbed $75.6M, contributing to an 11.7% reduction in share count over 5 years.

At a share price of $25.87, Amphastar trades at a trailing price-to-earnings ratio of 15.3x and an enterprise-value-to-EBITDA multiple of 7.6x, compared to medians of 24.6x and 12.0x for its US-listed Healthcare peers. Its price-to-sales ratio of 1.5x is also below the peer median of 4.1x. Over the past year, Amphastar returned 11.4%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock returned 35.4% compared to 83.0% for the index.

Wall Street analyst coverage comprises 0 Strong Buy, 0 Buy, 6 Hold, and 1 Sell ratings. The mean price target of $22.50 sits 13.0% below the last close of $25.87. For the fiscal year ending December 31, 2026, analysts estimate revenue of $747.7M and EPS of $2.97, reflecting an 8.6% decline in EPS. Amphastar has exceeded earnings estimates in 2 of the last 4 quarters, with its next earnings release scheduled for November 5, 2026.

This page is an AI-written research summary of Amphastar Pharmaceuticals, Inc. (AMPH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AMPH income statement, AMPH balance sheet, AMPH key metrics, AMPH analyst forecast, AMPH chart. See the AMPH stock overview for the latest quote and news.